Improving adherence to therapy and clinical outcomes while containing costs: Opportunities from the greater use of generic medications: Best practice advice from the clinical guidelines committee of the American college of physicians

Annals of Internal Medicine

Volumn 164, Issue 1, 2016, Pages 41-49

  Choudhry, Niteesh K ^a   Denberg, Thomas D ^b   Qaseem, Amir ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CARILION CLINIC   (United States)

^c AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPARATIVE EFFECTIVENESS; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; MEDICAID; MEDICARE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); DRUG UTILIZATION; ECONOMICS; THERAPEUTIC EQUIVALENCE; UNITED STATES;

COST SAVINGS; DRUG UTILIZATION; DRUGS, GENERIC; HUMANS; MEDICATION ADHERENCE; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 84953223821     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2427     Document Type: Article

References (86)

1. Yong PL, Saunders RS, Olsen LA, eds; Institute of Medicine (US) Roundtable on Evidence-Based Medicine. The Healthcare Imperative: Lowering Costs and Improving Outcomes: Workshop Series Summary. Washington, DC: National Academies Pr; 2010. [PMID: 21595114].
2. IMS Institute for Healthcare Informatics. Declining Medicine Use and Costs: For Better or Worse? A Review of the Use of Medicines in the United States in 2012. Parsippany, NJ: IMS Institute for Healthcare Informatics; 2013. Accessed at http://static.correofarmaceutico.com/docs/2013/05/20/usareport.pdf on 29 October 2015.
3. Campbell EG, Pham-Kanter G, Vogeli C, Iezzoni LI. Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians [Letter]. JAMA Intern Med. 2013;173: 237-9. [PMID: 23303297].
4. U.S. Department of Health and Human Services. Expanding the Use of Generic Drugs. Washington, DC: U.S. Department of Health and Human Services; 2010. Accessed at http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.shtml on 9 July 2014.
5. Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care. Med Care. 2007;45:109-15. [PMID: 17224772].
6. Gellad WF, Donohue JM, Zhao X, Mor MK, Thorpe CT, Smith J, et al. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison. Ann Intern Med. 2013;159:105-14. [PMID: 23752663].
7. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662-74. [PMID: 12187180].
8. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med. 2005;142: 891-7. [PMID: 15941695].
9. Brill A. Overspending on multi-source drugs in Medicaid. Washington, DC: American Enterprise Institute; 2011. Accessed at www.aei.org/papers/health/entitlements/overspending-on-multi-source-drugs-in-medicaid on 4 April 2011.
10. Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. Am Heart J. 2008;155:904-9. [PMID: 18440340].
11. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004; 291:1850-6. [PMID: 15100203].
12. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125:302.e1-7. [PMID: 22340932].
13. Cox E, Behn A, Mager D. Generic drug usage report. Maryland Heights, MO: Express Scripts; 2005.
14. Holahan J, Buettgens M, Carroll C, Dorn S. The Cost and Coverage Implications of the ACA Medicaid Expansion: National and State-by-State Analysis. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2012. Accessed at http://kaiserfamily foundation.files.wordpress.com/2013/01/8384.pdf on 4 August 2014.
15. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-9. [PMID: 17609491].
16. Shrank WH, Choudhry NK, Fischer MA, Avorn J, Powell M, Schneeweiss S, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153:633-40. [PMID: 21079218].
17. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91-9. [PMID: 21209444].
18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-30. [PMID: 15908846].
19. Stuart BC, Simoni-Wastila L, Zhao L, Lloyd JT, Doshi JA. Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care. 2009;32:647-9. [PMID: 19171724].
20. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15:450-6. [PMID: 19589012].
21. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-7. [PMID: 16476874].
22. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12:678-83. [PMID: 17090224].
23. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14: 813-8. [PMID: 19067498].
24. Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic and brandname statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161:400-7. [PMID: 25222387].
25. Rosenthal E. Officials question the rising costs of generic drugs. The New York Times. 8 October 2014:B9.
26. Fein AJ. Retail Generic Drug Inflation Reaches New Heights. Drug Channels. 12 August 2014. Accessed at www.drugchannels .net/2014/08/retail-generic-drug-inflation-reaches.html on 9 November 2015.
27. Strom BL. Generic drug substitution revisited. N Engl J Med. 1987;316:1456-62. [PMID: 3553952].
28. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and metaanalysis. JAMA. 2008;300:2514-26. [PMID: 19050195].
29. U.S. Food and Drug Administration. Thyroid Medications: Q & A with Mary Parks, M.D. Silver Spring, MD: U.S. Food and Drug Administration; 2008. Accessed at www.fda.gov/ForConsumers/Consumer Updates/ucm107377.htm on 4 August 2014.
30. U.S. Food and Drug Administration. Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg. Silver Spring, MD: U.S. Food and Drug Administration; 2015. Accessed at www.fda.gov/AboutFDA/CentersOffices/OfficeofMedical ProductsandTobacco/CDER/ucm153270.htm on 4 August 2014.
31. U.S. Food and Drug Administration. Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies. Silver Spring, MD: U.S. Food and Drug Administration; 2014. Accessed at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm322161.htm on 15 January 2015.
32. Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, et al; Warfarin Associated Research Projects and Other Endeavors (WARPED) Consortium. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011;31:386-93. [PMID: 21449627].
33. Ip S, Bonis P, Tatsioni A, Raman G, Chew P, Kupelnick B, et al. Comparative Effectiveness of Management Strategies For Gastroesophageal Reflux Disease. Comparative effectiveness review no. 1. AHRQ publication no. 06-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Accessed at http://effectivehealthcare.ahrq.gov/repFiles/GERD Final Report.pdf on 29 October 2015.
34. McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors: Final Report Update 5. Portland: Oregon Health & Science University; 2009. [PMID: 21089251].
35. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006:CD003491. [PMID: 16437456].
36. Gartlehner G, Hansen RA, Kahwati L, Lohr KN, Gaynes B, Carey T. Drug Class Review on Second Generation Antidepressants: Final Report. Portland: Oregon Health & Science University; 2006. [PMID: 20480925].
37. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:725-33. [PMID: 19017591].
38. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and metaanalysis. Drugs. 2010;70:605-21. [PMID: 20329806].
39. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-97. [PMID: 22080794].
40. Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, et al. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med. 2014;174:1955-62. [PMID: 25347323].
41. Grant RW, Pabon-Nau L, Ross KM, Youatt EJ, Pandiscio JC, Park ER. Diabetes oral medication initiation and intensification: patient views compared with current treatment guidelines. Diabetes Educ. 2011;37:78-84. [PMID: 21115980].
42. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30:2478-83. [PMID: 17623824].
43. Stewart WC, Sharpe ED, Stewart JA, Hott CE. The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%. Curr Eye Res. 2002;24:387-91. [PMID: 12434307].
44. Narayanaswamy A, Neog A, Baskaran M, George R, Lingam V, Desai C, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55: 127-31. [PMID: 17322603].
45. Hashemi M, Miraftabi A, Nilforoushan N, Ghasemi Falavarjani K, Pakdel F, Soudi R, et al. Comparison of the efficacy and tolerability of Xalatan® and Xalabiost (generic latanoprost) in adults with openangle glaucoma or ocular hypertension: a two-center, randomized, crossover trial. Iran J Ophthalmol. 2012;24:11-8.
46. Golan S, Rosenfeld E, Shemesh G, Kurtz S. Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same? Clin Exp Pharmacol Physiol. 2015;42:220-4. [PMID: 25345750].
47. Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N, et al. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma. 2013;22:707-12. [PMID: 22595934].
48. Brennan TA, Lee TH. Allergic to generics. Ann Intern Med. 2004; 141:126-30. [PMID: 15262668].
49. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients' perceptions of generic medications. Health Aff (Millwood). 2009;28:546-56. [PMID: 19276015].
50. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45:31-8. [PMID: 21205953].
51. Frisk P, Rydberg T, Carlsten A, Ekedahl A. Patients' experiences with generic substitution: a Swedish pharmacy survey. J Pharm Health Serv Res. 2011;2:9-15.
52. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy [Letter]. JAMA. 2008;299:1016-7. [PMID: 18319411].
53. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014;161:96-103. [PMID: 25023248].
54. Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013;173:202-8. [PMID: 23277164].
55. Banahan BF 3rd, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080-8. [PMID: 9382664].
56. Eban K. Dirty medicine. Fortune. 15 May 2013.
57. Wang B, Gagne JJ, Choudhry NK. The epidemiology of drug recalls in the United States [Letter]. Arch Intern Med. 2012;172:1109-10. [PMID: 22664942].
58. Helfand C. Top 10 generics makers by 2012 revenue. Fierce Pharma. 21 October 2013.
59. Steinman MA, Chren MM, Landefeld CS. What's in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med. 2007;22:645-8. [PMID: 17443372].
60. Shrank WH, Liberman JN, Fischer MA, Avorn J, Kilabuk E, Chang A, et al. The consequences of requesting "dispense as written". Am J Med. 2011;124:309-17. [PMID: 21435421].
61. Campbell EG. Doctors and drug companies-scrutinizing influential relationships. N Engl J Med. 2007;357:1796-7. [PMID: 17978288].
62. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood). 2010;29:1383-90. [PMID: 20606192].
63. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring, MD: U.S. Food and Drug Administration; 2014. Accessed at www.accessdata.fda.gov/scripts/cder/ob/default.cfm on 29 October 2015 .
64. Fischer MA, Vogeli C, Stedman M, Ferris T, Brookhart MA, Weissman JS. Effect of electronic prescribing with formulary decision support on medication use and cost. Arch Intern Med. 2008;168: 2433-9. [PMID: 19064827].
65. Stenner SP, Chen Q, Johnson KB. Impact of generic substitution decision support on electronic prescribing behavior. J Am Med Inform Assoc. 2010;17:681-8. [PMID: 20962131].
66. Davis D, O'Brien MA, Freemantle N, Wolf FM, Mazmanian P, Taylor-Vaisey A. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA. 1999;282:867-74. [PMID: 10478694].
67. Bhargava V, Greg ME, Shields MC. Addition of generic medication vouchers to a pharmacist academic detailing program: effects on the generic dispensing ratio in a physician-hospital organization. J Manag Care Pharm. 2010;16:384-92. [PMID: 20635829].
68. Shrank WH, Choudhry NK, Solomon DH, Snedden TM, Lee TH, Glynn RJ, et al. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009; 157:613-9. [PMID: 19332186].
69. Scott AB, Culley EJ, O'Donnell J. Effects of a physician office generic drug sampling system on generic dispensing ratios and drug costs in a large managed care organization. J Manag Care Pharm. 2007;13:412-9. [PMID: 17605512].
70. Rathe J, Larsen P, Andersen M, Paulsen M, Jarbøl D, Thomsen J, et al. Associations between generic substitution and patients' attitudes, beliefs and experiences. Eur J Clin Pharmacol. 2013;69:1827-36. [PMID: 23765409].
71. O'Malley AJ, Frank RG, Kaddis A, Rothenberg BM, McNeil BJ. Impact of alternative interventions on changes in generic dispensing rates. Health Serv Res. 2006;41:1876-94. [PMID: 16987306].
72. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349: 2224-32. [PMID: 14657430].
73. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41:398-406. [PMID: 12618643].
74. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and copayment on rational drug use. Cochrane Database Syst Rev. 2008: CD007017. [PMID: 18254125].
75. Kelton CM, Chang LV, Kreling DH. State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05. Health Aff (Millwood). 2013;32:1204-11. [PMID: 23836735].
76. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051-63. [PMID: 12968816].
77. Holmes DR Jr, Becker JA, Granger CB, Limacher MC, Page RL 2nd, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation. 2011;124:1290-310. [PMID: 21844072].
78. Sanfélix-Gimeno G, Franklin JM, Shrank WH, Carlo M, Tong AY, Reisman L, et al. Did HEDIS get it right? Evaluating the quality of a quality measure: adherence to b-blockers and cardiovascular outcomes after myocardial infarction. Med Care. 2014;52:669-76. [PMID: 24926716].
79. Centers for Medicare & Medicaid Services. Five-Star Quality Rating System. Baltimore: Centers for Medicare & Medicaid Services; 2015. Accessed at www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandComplianc/FSQRS.html on 29 October 2015.
80. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med. 2006;355:375-84. [PMID: 16870916].
81. Lindenauer PK, Remus D, Roman S, Rothberg MB, Benjamin EM, Ma A, et al. Public reporting and pay for performance in hospital quality improvement. N Engl J Med. 2007;356:486-96. [PMID: 17259444].
82. Petersen LA, Woodard LD, Urech T, Daw C, Sookanan S. Does pay-for-performance improve the quality of health care? Ann Intern Med. 2006;145:265-72. [PMID: 16908917].
83. Easthall C, Song F, Bhattacharya D. A meta-analysis of cognitivebased behaviour change techniques as interventions to improve medication adherence. BMJ Open. 2013;3. [PMID: 23935093].
84. Stacey D, LégaréF, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431. [PMID: 24470076].
85. Rogers T, Milkman KL, Volpp KG. Commitment devices: using initiatives to change behavior. JAMA. 2014;311:2065-6. [PMID: 24777472].
86. Choudhry NK, Cox ER, Fischer MA, Mehta J, Shrank WH. Setting prices for generic medications: a survey of patients' perceptions. Am J Pharm Benefits. 2010;2:33-8.